Buy & Sell Levi Strauss & Co. (LEVI) – Levi Strauss & Co. Price Today
Aura AI Summary
Key Stats
- $8.47BMarket Cap
- Consumer CyclicalSector
- -20.59%3M Drawdown
- $9.97BEnterprise Value
- 2.54%Dividend Yield
- 67 daysTypical Hold Time
Levi Strauss & Co. (LEVI) is currently valued at a market capitalization of $8.47B, with an enterprise value of $9.97B. Over the past 52 weeks, Levi Strauss & Co. has traded between a low of $16.72 and a high of $24.66, highlighting its annual price range. Over the past three months, Levi Strauss & Co. has recorded a drawdown of -20.59%, reflecting recent price volatility. Levi Strauss & Co. offers a dividend yield of 2.54%, with the most recent dividend of $0.14 paid on 22 Apr 26. On average, investors hold Levi Strauss & Co. for approximately 67 days, indicating typical investor behavior on the platform.
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Most Recent News
Investigation launched over Regeneron’s optimistic trial claims that preceded stock drop.
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...

Investigation launched into Prestige Consumer Healthcare over missed earnings and undisclosed acquisition
Levi & Korsinsky has started an investigation into Prestige Consumer Healthcare following the company's failure to meet its Q4 and full-year financial projections, including adjusted gross margin, free cash flow, and adjusted EPS. Additionally, Prest...

Investigation launched into TriSalus Life Sciences after Q1 revenue misses estimates and cuts full-year guidance
Levi & Korsinsky has started an investigation into TriSalus Life Sciences following the company's Q1 2026 revenue of $8.9 million, which missed Wall Street's $9.4 million estimate. The company also lowered its full-year 2026 revenue forecast to $54 m...
